CompletedNot Applicable

Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer

Sweden118 participantsStarted 2015-05

Plain-language summary

The study's aim is to define imaging and molecular bio-markers for prediction of radiotherapy response of squamous cell carcinomas, in an early treatment phase.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Morphologically (pathology or cytology) verified, previously untreated squamous cell carcinoma (SCC) of the oral cavity, oropharynx, uterine cervix, oesophagus or lung.
. The patient should be planned for treatment with radiotherapy alone or in combination with concomitant medical therapy
. The tumour shall be radiologically and/or visually identifiable and accessible for biopsy without the need for general anaesthesia or other major interventions
. The patient must be at least 18 years of age, able to understand the given information and, leave a written informed consent to participate

Exclusion criteria

. The patient is unwilling to participate in the study
. Patients with adjuvant post-operative radiotherapy (i.e. no visible remaining tumour)
. Pregnancy or lactation
. Contraindications to investigations with MRI, gadolinium contrast or PET-tracers
. Patients with an estimated glomerular filtration rate (GFR) \<60 ml/min/1.73m2.
. Severe co-morbidities that are judged to significantly compromise survival in a two-years perspective.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Loco regional control

Timeframe: 2 years

Trial details

NCT IDNCT02379039

SponsorUmeå University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-05

View on ClinicalTrials.gov More Squamous Carcinoma trials